ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise
During the American Society of Clinical Oncology (ASCO) meeting 2026, data were presented for a number of cancer vaccines, including…
01 Jun 2026
ASCO26: key readouts in lung cancer
As professionals from across the oncology landscape gather at the 2026 American Society of Clinical Oncology (ASCO) congress in Chicago, many are looking to key readouts in lung cancer, the…
01 Jun 2026
ASCO26: BMS and J&J debut shining multiple myeloma data
Several companies have presented compelling data from multiple myeloma studies at the 2026 American Society of Clinical Oncology (ASCO) meeting. Data was announced by both Bristol Myers Squibb (BMS) and…
01 Jun 2026
Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide
Eli Lilly and Company has entered a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide (a LAPS GLP-2 analogue),…
01 Jun 2026
FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy for adult patients with BCG-naïve,…
29 May 2026
GSK’s Nucala secures NICE COPD endorsement
In another landmark for GSK’s blockbuster respiratory drug, Nucala (mepolizumab), the UK’s health watchdog has recommended the therapy’s use by the UK National Health Service (NHS) in patients with chronic…
29 May 2026
Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal
Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and development of a portfolio of 12 early-stage cancer medications. The…